{
  "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
  "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
  "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 25,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "The slide uses a standard comparison table format to contrast a competitor (Resmetirom) with the company's own asset (DA-1241).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/8",
  "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
  "deckJsonHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7.json",
  "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-announces-positive-topline-results-pivotal-phase-3",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "093ccd86-6eed-44ef-8843-0d725aec810e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.68,
        "w": 0.9,
        "x": 0.05,
        "y": 0.21
      },
      "kind": "table",
      "text": "Comparison table between Resmetirom and DA-1241 across developer, indication, status, action, dosage, efficacy, safety, and differentiation.",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce7f7d87-1c4f-4b75-a379-ba73ee72db41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "DA-1241: Competitive Differentiation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2eb9572-ffb6-4a52-8b31-6a1ac14d56b1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "b2eb7c9b-eac6-4b61-a9b0-46efb7f5e3d9",
      "evidence": "Direct side-by-side comparison of product attributes against a competitor.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "fc2a383c-968e-4c6a-836f-347c2e1bb09a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 7-14 detail the solution, including DA-1241 and its competitive differentiation",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 8,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "aaa7b418-9181-47ba-b6b2-b63828815fff",
      "evidence": "Slides 8-9 discuss DA-1241's competitive differentiation",
      "position": 0,
      "objective": "How does DA-1241 differentiate from existing treatments?",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    },
    {
      "to": 24,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
      "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
      "position": 1,
      "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}